SCHEMBL229446

SCHEMBL229446

COc1cc(C(=O)O)ccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 6/20 0.57
KDM4E B2RXH2 5/20 0.57
KDM6B O15054 3/20 0.57
KDM5C P41229 3/20 0.57
KDM2A Q9Y2K7 3/20 0.57
KDM3A Q9Y4C1 3/20 0.57
KDM5A P29375 3/20 0.55
KDM5B Q9UGL1 3/20 0.55
KDM4A O75164 2/20 0.55
ALDH1A1 P00352 2/20 0.55
TET3 O43151 1/20 0.55
BBOX1 O75936 1/20 0.55
MAPT P10636 1/20 0.55
ASPH Q12797 1/20 0.55
KDM4D Q6B0I6 1/20 0.55
TET2 Q6N021 1/20 0.55
ALKBH5 Q6P6C2 1/20 0.55
KDM7A Q6ZMT4 1/20 0.55
KDM8 Q8N371 1/20 0.55
TET1 Q8NFU7 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29556902 1.00 KDM4C (0.57) KDM4CKDM4EKDM6BKDM5CKDM2A
Hydrochloric Acid SCHEMBL5564185 0.98 KDM4C (0.56) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL27841468 0.86 KCNK3 (0.52) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL29640109 0.85 KCNK3 (0.55) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL12640026 0.85 KCNK3 (0.55) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL31637653 0.83 KCNK3 (0.50) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL2431121 0.83 KCNK3 (0.50) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL445784 0.83 NNMT (0.56) KDM4EKDM5CKDM5BALDH1A1KCNK3
SCHEMBL29587235 0.83 KDM4E (0.61) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL16168468 0.83 KCNK3 (0.50) KDM4CKDM4EKDM6BKDM5CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118420919-A Metal organic framework material with trivalent boron blocked Lewis acid-base pair with fixed structures at two ends, preparation method and application thereof 武汉大学 2024-08-02 CN claimed
EP-2822931-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF Inception 2, Inc. (US) 2015-01-14 EP claimed
WO-2013134562-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2013-09-12 WO claimed
WO-2008013334-A1 DEFORMYLASE INHIBITOR, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION COMPRISING THE SAME PROMEDITECH INC. (KR) 2008-01-31 WO claimed
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
EP-4724446-A1 OXAZOLOPYRIDIN-7(4H)-ONE WRN INHIBITORS Nimbus Wadjet, Inc. (US) 2026-04-15 EP disclosed
US-12590090-B2 Pyrimidine-and nitrogen-containing bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2026-03-31 US disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
EP-4695246-A1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES Syngenta Crop Protection AG (CH) 2026-02-18 EP disclosed
EP-4665733-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 Bristol-Myers Squibb Company (US) 2025-12-24 EP disclosed
EP-4650002-A1 ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) Ludwig-Maximilians-Universität (DE) 2025-11-19 EP disclosed
EP-1357116-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR ITS SALT YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-10-29 EP disclosed
EP-0550111-B1 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them SANOFI SA (FR) 1999-04-14 EP disclosed
US-5856349-A 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof SANOFI (FR) 1999-01-05 US disclosed
US-5652254-A TREATMENT OF DEGENERATIVE DISEASES, RHEUMATOID ARTHRITIS, PSORIASIS, CYSTIC FIBROSIS SANOFI, S.A. (FR) 1997-07-29 US disclosed
US-5563163-A TREATMENT OF DEGENERATIVE DISEASES STERLING WINTHROP, INC. (US) 1996-10-08 US disclosed
US-5488062-A 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC. (US) 1996-01-30 US disclosed
US-5376653-A A protease enzyme inhibitor for treating degenerative diseases , respiratory system disorders, rheumatoid arthritis and pancreatitis STERLING WINTHROP INC. (US) 1994-12-27 US disclosed
EP-0550111-A1 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them STERLING WINTHROP INC. (US) 1993-07-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH KDM4C 3490/4885KDM4E 3565/4885KDM6B 3795/4885
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors KCNT1, KCNT2, KCNJ2 KDM4C 2851/4885KDM4E 2324/4885KDM6B 1927/4885
US-12590090-B2 Pyrimidine-and nitrogen-containing bicyclic compound IRAK1, IRAK4, IRAK2 KDM4C 845/4885KDM4E 1029/4885KDM6B 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.